These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34144133)

  • 1. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up.
    Operti MC; Bernhardt A; Grimm S; Engel A; Figdor CG; Tagit O
    Int J Pharm; 2021 Aug; 605():120807. PubMed ID: 34144133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation.
    Operti MC; Bernhardt A; Sincari V; Jager E; Grimm S; Engel A; Hruby M; Figdor CG; Tagit O
    Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35214009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and optimization of microfluidic assisted manufacturing process to produce PLGA nanoparticles.
    Chiesa E; Bellotti M; Caimi A; Conti B; Dorati R; Conti M; Genta I; Auricchio F
    Int J Pharm; 2022 Dec; 629():122368. PubMed ID: 36343906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translating the Manufacture of Immunotherapeutic PLGA Nanoparticles from Lab to Industrial Scale: Process Transfer and In Vitro Testing.
    Operti MC; Bernhardt A; Pots J; Sincari V; Jager E; Grimm S; Engel A; Benedikt A; Hrubý M; De Vries IJM; Figdor CG; Tagit O
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases.
    Alsaab HO; Alharbi FD; Alhibs AS; Alanazi NB; Alshehri BY; Saleh MA; Alshehri FS; Algarni MA; Almugaiteeb T; Uddin MN; Alzhrani RM
    Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLGA-based nanoparticles: an overview of biomedical applications.
    Danhier F; Ansorena E; Silva JM; Coco R; Le Breton A; Préat V
    J Control Release; 2012 Jul; 161(2):505-22. PubMed ID: 22353619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles.
    Li X; Jiang X
    Adv Drug Deliv Rev; 2018 Mar; 128():101-114. PubMed ID: 29277543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating the fabrication of protein-loaded poly(lactic-co-glycolic acid) nanoparticles from bench to scale-independent production using microfluidics.
    Roces CB; Christensen D; Perrie Y
    Drug Deliv Transl Res; 2020 Jun; 10(3):582-593. PubMed ID: 31919746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities.
    Agrahari V; Agrahari V
    Drug Discov Today; 2018 May; 23(5):974-991. PubMed ID: 29406263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP.
    Zhi K; Raji B; Nookala AR; Khan MM; Nguyen XH; Sakshi S; Pourmotabbed T; Yallapu MM; Kochat H; Tadrous E; Pernell S; Kumar S
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles.
    Dormont F; Rouquette M; Mahatsekake C; Gobeaux F; Peramo A; Brusini R; Calet S; Testard F; Lepetre-Mouelhi S; Desmaële D; Varna M; Couvreur P
    J Control Release; 2019 Aug; 307():302-314. PubMed ID: 31260754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives.
    Souto EB; Blanco-Llamero C; Krambeck K; Kiran NS; Yashaswini C; Postwala H; Severino P; Priefer R; Prajapati BG; Maheshwari R
    Acta Biomater; 2024 May; 180():1-17. PubMed ID: 38604468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
    Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
    Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.
    Taha MS; Padmakumar S; Singh A; Amiji MM
    Drug Deliv Transl Res; 2020 Jun; 10(3):766-790. PubMed ID: 32170656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Nanomedicine: A Revolution at the Nanoscale.
    Fornaguera C; García-Celma MJ
    J Pers Med; 2017 Oct; 7(4):. PubMed ID: 29023366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment.
    Zhang X; Dong Y; Zeng X; Liang X; Li X; Tao W; Chen H; Jiang Y; Mei L; Feng SS
    Biomaterials; 2014 Feb; 35(6):1932-43. PubMed ID: 24315578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.